Content Validation of the Movement Disorder-Childhood Rating Scale (MD-CRS) for Dyskinetic Cerebral Palsy.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
04 2023
Historique:
received: 08 04 2022
revised: 09 09 2022
accepted: 11 12 2022
medline: 28 3 2023
pubmed: 13 2 2023
entrez: 12 2 2023
Statut: ppublish

Résumé

Dyskinetic cerebral palsy (DCP), a lifelong neurological disorder beginning in early childhood, manifests with hyperkinetic movements and dystonia. The Movement Disorder-Childhood Rating Scale (MD-CRS) is a clinician-reported outcome measure assessing the intensity of movement disorders and their effect on daily life in pediatric patients. Content validity of clinical outcome assessments is key to accurately capturing patient perspective. Evidence demonstrating content validity of the MD-CRS in patients with DCP is needed. This study captures input from patients with DCP and their caregivers regarding the content validity of the MD-CRS. This qualitative, noninterventional, cross-sectional study included interviews with children/adolescents (aged six to 18 years) with DCP and caregivers of children with DCP. Participants were asked to describe body regions and daily functions affected by DCP. Caregivers also reviewed MD-CRS Part I to evaluate the relevance of the items and corresponding response options. Descriptions of DCP were coded and mapped to MD-CRS items and response options. Caregiver feedback on MD-CRS Part I was analyzed using inductive content analysis. Eight patients and 12 caregivers were interviewed. Participants confirmed that the body regions and activities listed in the MD-CRS were affected by DCP and that involuntary movements interfered with all motor, oral/verbal, self-care, and video protocol activities. Caregivers endorsed the response options for 12 of 15 items in MD-CRS Part I and suggested clarifications for others. Participants confirmed that affected body regions and activities listed in the MD-CRS were relevant to their experience with DCP, demonstrating the content validity of this tool in children/adolescents with DCP.

Sections du résumé

BACKGROUND
Dyskinetic cerebral palsy (DCP), a lifelong neurological disorder beginning in early childhood, manifests with hyperkinetic movements and dystonia. The Movement Disorder-Childhood Rating Scale (MD-CRS) is a clinician-reported outcome measure assessing the intensity of movement disorders and their effect on daily life in pediatric patients. Content validity of clinical outcome assessments is key to accurately capturing patient perspective. Evidence demonstrating content validity of the MD-CRS in patients with DCP is needed. This study captures input from patients with DCP and their caregivers regarding the content validity of the MD-CRS.
METHODS
This qualitative, noninterventional, cross-sectional study included interviews with children/adolescents (aged six to 18 years) with DCP and caregivers of children with DCP. Participants were asked to describe body regions and daily functions affected by DCP. Caregivers also reviewed MD-CRS Part I to evaluate the relevance of the items and corresponding response options. Descriptions of DCP were coded and mapped to MD-CRS items and response options. Caregiver feedback on MD-CRS Part I was analyzed using inductive content analysis.
RESULTS
Eight patients and 12 caregivers were interviewed. Participants confirmed that the body regions and activities listed in the MD-CRS were affected by DCP and that involuntary movements interfered with all motor, oral/verbal, self-care, and video protocol activities. Caregivers endorsed the response options for 12 of 15 items in MD-CRS Part I and suggested clarifications for others.
CONCLUSIONS
Participants confirmed that affected body regions and activities listed in the MD-CRS were relevant to their experience with DCP, demonstrating the content validity of this tool in children/adolescents with DCP.

Identifiants

pubmed: 36774682
pii: S0887-8994(22)00270-3
doi: 10.1016/j.pediatrneurol.2022.12.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-71

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Daniel O Claassen (DO)

Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: daniel.claassen@vumc.org.

Heather R Riordan (HR)

Vanderbilt University Medical Center, Nashville, Tennessee.

Leon S Dure (LS)

Heersink School of Medicine, Birmingham, Alabama.

Roberta Battini (R)

IRCCS Fondazione Stella Maris, Viale de Tirreno, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Lungarno Antonio Pacinotti, Pisa, Italy.

Alma Cortez (A)

Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania.

Mark Forrest Gordon (MF)

Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania.

Meaghan O'Connor (M)

QualityMetric Incorporated, LLC, Johnston, Rhode Island.

Kristi Jackson (K)

QualityMetric Incorporated, LLC, Johnston, Rhode Island.

April Foster (A)

QualityMetric Incorporated, LLC, Johnston, Rhode Island.

Mark Kosinski (M)

QualityMetric Incorporated, LLC, Johnston, Rhode Island.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH